Repeated magnetic resonance imaging in esophageal cancer for adaptive radiation treatment planning during chemoradiotherapy. - REACT

niversitair Medisch Centrum Utrecht0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•- Histologically confirmed squamous-cell carcinoma, adenocarcinoma or large-cell undifferentiated carcinoma of the esophagus or esophagogastric junction (i.e. tumors involving both cardia and esophagus on endoscopy) - For nCRT: potentially resectable tumor (cT1b-4b N0-3 M0) and undergoing preoperative chemoradiation according to CROSS-regimen - For dCRT: unresectable tumor (T4bNxM0) or medically unfit patient for surgery due to comorbidities based on multidisciplinary consensus, undergoing definitive chemoradiation - Age>18 years - Signed informed consent

•- Patients who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht. -Patients who meet exclusion criteria for Gadovist gadolinium (Glomerular Filtration Rate (GFR) of <35 mL/min/1.73m2, *according to clinical protocol*). - Patients with a known Gadovist allergy - Patients having difficulty understanding Dutch - History of previous radiotherapy for thoracic, gastric or head and neck tumors - Pregnant or breast-feeding patients

发起方

niversitair Medisch Centrum Utrecht